chr12-112477651-T-A
Variant summary
Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PM1PM2PM5PP2PP3PP5_Very_Strong
The NM_002834.5(PTPN11):c.854T>A(p.Phe285Tyr) variant causes a missense, splice region change. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. 2/3 splice prediction tools predict no significant impact on normal splicing. Variant has been reported in ClinVar as Likely pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. F285L) has been classified as Pathogenic.
Frequency
Consequence
NM_002834.5 missense, splice_region
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 16 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
PTPN11 | NM_002834.5 | c.854T>A | p.Phe285Tyr | missense_variant, splice_region_variant | 8/16 | ENST00000351677.7 | NP_002825.3 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
PTPN11 | ENST00000351677.7 | c.854T>A | p.Phe285Tyr | missense_variant, splice_region_variant | 8/16 | 1 | NM_002834.5 | ENSP00000340944.3 | ||
PTPN11 | ENST00000635625.1 | c.854T>A | p.Phe285Tyr | missense_variant, splice_region_variant | 8/15 | 5 | ENSP00000489597.1 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 31
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
not provided Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Jun 15, 2023 | Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Missense variants in this gene are often considered pathogenic (HGMD); This variant is associated with the following publications: (PMID: 31573083, 33009502, 29493581, 30896080) - |
Cardiovascular phenotype Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Aug 03, 2018 | The p.F285Y pathogenic mutation (also known as c.854T>A) is located in coding exon 8 of the PTPN11 gene. This change occurs in the first base pair of coding exon 8. The phenylalanine at codon 285 is replaced by tyrosine, an amino acid with highly similar properties. This mutation is located in the protein tyrosine phosphatase (PTP) functional domain of the SHP-2 protein, and is predicted to disrupt the interdomain interaction with the N-SH2 domain, which normally stabilizes the inactive conformation of the protein. Alterations at the same amino acid position (p.F285I, p.F285L, p.F285S and p.F285C) have been described in individuals with Noonan Syndrome (Tartaglia M et al, Am. J. Hum. Genet. 2002 Jun; 70(6):1555-63; Kosaki K et al, J. Clin. Endocrinol. Metab. 2002 Aug; 87(8):3529-33; Bertola DR et al, Genet. Test. 2006; 10(3):186-91; Tartaglia M et al, Am. J. Hum. Genet. 2006 Feb; 78(2):279-90; Ferrero GB et al, Eur J Med Genet 2008 Jul; 51(6):566-72; Essawi ML et al, J. Formos. Med. Assoc. 2013 Nov; 112(11):707-12). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. - |
RASopathy Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Jun 07, 2021 | Variant summary: PTPN11 c.854T>A (p.Phe285Tyr) results in a conservative amino acid change located in the PTP type protein phosphatase domain (IPR000242) of the encoded protein sequence. Three of five in-silico tools predict a benign effect of the variant on protein function. 4/4 computational tools predict no significant impact on normal splicing. However, these predictions have yet to be confirmed by functional studies. The variant was absent in 251350 control chromosomes (gnomAD). c.854T>A has been reported in the literature in individuals affected with Noonan syndrome or Noonan syndrome with multiple lentigines (Yu_2019). These data indicate that the variant may be associated with disease. Additionally, other variants at the same amino acid residue (Phe285Cys, Phe285Ile, Phe285Leu, Phe285Ser) have also been reported in association with Noonan syndrome, further supporting that this residue has clinical significance. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014. Based on the evidence outlined above, the variant was classified as likely pathogenic. - |
Noonan syndrome Uncertain:1
Uncertain significance, no assertion criteria provided | clinical testing | Service de Génétique Moléculaire, Hôpital Robert Debré | - | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at